BioMarin Pharmaceutical has struck a deal to purchase fellow biotechnology firm Amicus Therapeutics for about $4.8 billion in money.
Source link
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
Related Posts
Amazon, Intel shares fall after earnings amid AI spending concerns
CFOTO | Future Publishing | Getty Pictures Amazon and Intel shares had been down in premarket buying and selling on…
Why Humans Are Still More Cost-Effective Than AI Compute
The economics of AI don’t at all times match expectations. Excessive compute, infrastructure, and reliability prices imply human labor stays…
Chinese EV firms take fight to European automakers on their home turf
Xpeng CEO He Xiaopeng speaks to reporters on the electrical carmaker’s stand on the IAA auto present in Munich, Germany…